Abbott Laboratories 2024 Q2 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Abbott Laboratories is a global healthcare company operating through four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The company reported 1,739,897,004 common shares outstanding as of the period end.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $10,377 million | $9,978 million | $20,341 million | $19,725 million |
| Operating Earnings | $1,669 million | $1,542 million | $3,055 million | $3,051 million |
| Net Earnings | $1,302 million | $1,375 million | $2,527 million | $2,693 million |
| Diluted EPS | $0.74 | $0.78 | $1.44 | $1.53 |
| Operating Cash Flow (YTD) | $2,985 million (vs. $2,346 million YTD 2023) | |||
| Cash & Equivalents | $6,987 million (as of June 30, 2024) | |||
| Total Debt | $14,754 million (Current: $1,615m; Long-term: $13,139m) | |||
| Gross Margin | 51.1% (Q2 2024) vs. 50.1% (Q2 2023) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.0% in Q2 2024. Excluding foreign exchange impacts, sales grew 7.5%. Growth was driven by Medical Devices (+12.4% ex-FX) and Nutritional Products (+7.1% ex-FX), partially offset by a decline in Diagnostic Products due to lower COVID-19 testing demand.
- COVID-19 Impact: COVID-19 testing sales dropped significantly to $102 million in Q2 2024 from $263 million in Q2 2023. Excluding these sales, total net sales increased 5.7% in the quarter.
- Profitability: While operating earnings increased, Net Earnings decreased 5.3% in Q2 2024 compared to the prior year, primarily due to a $143 million loss on the sale of a non-core business in the Established Pharmaceutical Products segment.
- Foreign Exchange: A stronger U.S. dollar negatively impacted reported sales by 3.5% in Q2 2024.
Outlook, Risks, and Unusual Items
- Unusual Items: The company recorded a $143 million loss on the divestiture of a non-core business and $87 million in restructuring charges ($59 million severance, $28 million asset impairment) related to streamlining operations and discontinuing the ZonePerfect product line.
- Legal Proceedings: In July 2024, a jury awarded a plaintiff $495 million in a lawsuit alleging Abbott's preterm infant formula caused necrotizing enterocolitis (NEC). Abbott plans to appeal and has not recorded a reserve, citing uncertainty in estimating potential losses.
- Tax Contingencies: Abbott received Statutory Notices of Deficiency (SNOD) from the IRS for tax years 2017, 2018, and 2019 totaling over $600 million, and a Revenue Agent's Report for 2020 assessing an additional $443 million. The company intends to contest these assessments.
- Dividends: The quarterly dividend was increased to $0.55 per share, a 7.8% increase from the prior year.
Investor Verification Checklist
- COVID-19 Normalization: Verify the trajectory of non-COVID diagnostic sales to confirm the sustainability of the segment's recovery.
- Legal Exposure: Monitor the appeal process of the $495 million NEC verdict and the potential for similar litigation outcomes.
- Tax Resolution: Track the status of the IRS disputes regarding income reallocation, which could impact future effective tax rates and cash flows.
- Medical Devices Growth: Confirm continued double-digit growth in Diabetes Care (FreeStyle Libre) and Electrophysiology segments.
- Restructuring Execution: Assess the realization of cost savings from the $87 million in restructuring charges and the discontinuation of ZonePerfect.